Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The monoclonal antibody J591 is being investigated as therapy for patients with prostate
cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin). The study is
an open-label, non-randomized phase II study for patients with documented hormone refractory
prostate cancer.